Robert Schaub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Schaub has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Anjali Kumar
1 shared publication- Cecile V. Denis
HITh, UMR_S1176, INSERM, Université Paris-Saclay, Le Kremlin-Bicêtre, France
1 shared publication D. Duerschmied
Immune Disease Institute and Department of Pathology, Harvard Medical School, Boston, MA, USA
1 shared publicationD.D. Wagner
Immune Disease Institute and Department of Pathology, Harvard Medical School, Boston, MA, USA
1 shared publicationDanielle Libersan
1 shared publication- Denisa D. Wagner
CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
1 shared publication
Latest Publications
- 15 July 2011
- Published by Elsevier in Biochemical Pharmacology
- Vol. 82 (2) , 91-98
Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia
- 15 July 2011
- Published by Elsevier in Biochemical Pharmacology
- Vol. 82 (2) , 91-98
Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia
- 31 October 2010
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 10 (5) , 531-533
Evaluating the biological complexity of animal models of human disease and emerging therapeutic modalities
- 31 October 2010
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 10 (5) , 531-533
Evaluating the biological complexity of animal models of human disease and emerging therapeutic modalities
- 1 July 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (7) , 1155-1162
Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779
- 1 July 2009
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 7 (7) , 1155-1162
Inhibition of von Willebrand factor‐mediated platelet activation and thrombosis by the anti‐von Willebrand factor A1‐domain aptamer ARC1779
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 91 (06) , 1186-1193
Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln
- 1 January 2004
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 91 (06) , 1186-1193
Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln
- 15 January 2001
- Published by American Society of Hematology in Blood
- Vol. 97 (2) , 465-472
Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models
Interleukin (IL)-11 is a cytokine with thrombopoietic activity that has been shown to increase plasma von Willebrand factor (vWf) in preliminary clinical studies. This led to further evaluation of the effect of recombinant human (rh)IL-11 on vWf and factor VIII (FVIII) secretion. In vitro, rhIL-11 did not increase vWf production by cultured endothelial cells, which suggests an indirect mechanism. Also, in vivo, plasma vWf was not elevated in mice shortly after a single intravenous (IV) bolus injection of 250 or 1000 μg/kg rhIL-11. The effect of continuous exposure to rhIL-11 was accessed by treating wild type mice for 7 consecutive days with subcutaneous 250 μg/kg/d rhIL-11. Platelet counts increased by 25% and 40% after 4 and 7 days, respectively. Plasma vWf and FVIII levels increased 2-fold after 4 and 7 days. Surprisingly, no effect of rhIL-11 on vWf or FVIII messenger RNA was observed, which suggests that the regulation by rhIL-11 occurs after transcription. No increase in soluble P-selectin was observed after rhIL-11 treatment, indicating that platelet activation is not the source of elevated vWf. Similarly to wild type mice, vWf heterozygous mice responded to rhIL-11 treatment by a significant increase in platelet counts and vWf and FVIII levels. Importantly, in vWf-deficient mice, rhIL-11 also induced a significant increase in FVIII independent of vWf and was able to reduce skin bleeding time. These results suggest that a clinical evaluation of the effects of rhIL-11–induced vWf/FVIII elevation in maintaining hemostasis in mild hemophilia A or von Willebrand disease would be worthwhile.
- 15 January 2001
- Published by American Society of Hematology in Blood
- Vol. 97 (2) , 465-472
Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models
Interleukin (IL)-11 is a cytokine with thrombopoietic activity that has been shown to increase plasma von Willebrand factor (vWf) in preliminary clinical studies. This led to further evaluation of the effect of recombinant human (rh)IL-11 on vWf and factor VIII (FVIII) secretion. In vitro, rhIL-11 did not increase vWf production by cultured endothelial cells, which suggests an indirect mechanism. Also, in vivo, plasma vWf was not elevated in mice shortly after a single intravenous (IV) bolus injection of 250 or 1000 μg/kg rhIL-11. The effect of continuous exposure to rhIL-11 was accessed by treating wild type mice for 7 consecutive days with subcutaneous 250 μg/kg/d rhIL-11. Platelet counts increased by 25% and 40% after 4 and 7 days, respectively. Plasma vWf and FVIII levels increased 2-fold after 4 and 7 days. Surprisingly, no effect of rhIL-11 on vWf or FVIII messenger RNA was observed, which suggests that the regulation by rhIL-11 occurs after transcription. No increase in soluble P-selectin was observed after rhIL-11 treatment, indicating that platelet activation is not the source of elevated vWf. Similarly to wild type mice, vWf heterozygous mice responded to rhIL-11 treatment by a significant increase in platelet counts and vWf and FVIII levels. Importantly, in vWf-deficient mice, rhIL-11 also induced a significant increase in FVIII independent of vWf and was able to reduce skin bleeding time. These results suggest that a clinical evaluation of the effects of rhIL-11–induced vWf/FVIII elevation in maintaining hemostasis in mild hemophilia A or von Willebrand disease would be worthwhile.